AC Immune Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de AC Immune han disminuido a una tasa media anual de -20.2%, mientras que en la industria Biotechs los beneficios crecieron en un 7.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 52.3% al año.

Información clave

-20.2%

Tasa de crecimiento de los beneficios

-17.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	-52.3%
Rentabilidad financiera	-30.6%
Margen neto	-97.3%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero AC Immune. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:IMR Ingresos, gastos y beneficios (CHF Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 24	41	-40	17
30 Jun 24	15	-61	17
31 Mar 24	15	-55	16
31 Dec 23	15	-54	15
30 Sep 23	0	-68	15
30 Jun 23	4	-67	15
31 Mar 23	4	-69	16
31 Dec 22	4	-71	16
30 Sep 22	4	-73	14
30 Jun 22	0	-76	16
31 Mar 22	0	-75	17
31 Dec 21	0	-73	18
30 Sep 21	1	-71	19
30 Jun 21	2	-74	19
31 Mar 21	3	-71	18
31 Dec 20	15	-62	19
30 Sep 20	15	-62	19
30 Jun 20	47	-25	18
31 Mar 20	48	-26	17
31 Dec 19	110	45	16
30 Sep 19	111	50	15
30 Jun 19	80	18	14
31 Mar 19	81	24	13
31 Dec 18	7	-51	12
30 Sep 18	22	-32	12
30 Jun 18	21	-27	11
31 Mar 18	20	-29	10
31 Dec 17	20	-26	10
30 Sep 17	5	-35	10
30 Jun 17	6	-36	10
31 Mar 17	25	-10	9
31 Dec 16	23	-7	8
30 Sep 16	22	-8	5
30 Jun 16	45	21	4
31 Mar 16	39	17	4
31 Dec 15	39	20	3
30 Sep 15	65	46	4
30 Jun 15	41	21	4
31 Mar 15	28	10	3
31 Dec 14	30	11	3
31 Dec 13	9	-11	3

Ingresos de calidad: IMR actualmente no es rentable.

Margen de beneficios creciente: IMR actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: IMR no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 20.2% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de IMR en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: IMR no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-18.2%).

Rentabilidad financiera

Alta ROE: IMR tiene una rentabilidad financiera negativa (-30.63%), ya que actualmente no es rentable.

AC Immune Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Third quarter 2020 earnings released: CHF0.26 loss per share

First half earnings released

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

New major risk - Revenue and earnings growth

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Forecast to breakeven in 2025

Forecast to breakeven in 2026

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

New major risk - Revenue and earnings growth

AC Immune SA Announces Executive Changes

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

New 90-day high: €5.57

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: €5.17

AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

AC Immune Sa Appoints Carl H. June as Board of Directors

AC Immune SA Hires Johannes R. Streffer as Chief Medical Officer

Revenue beats expectations

Third quarter 2020 earnings released: CHF0.26 loss per share

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

New 90-day low: €3.83

AC Immune SA Announces EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

New 90-day low: €4.25

First half earnings released

New 90-day high - €7.95

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado